GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Deal with DoveTree, established by Harvard professor Gregory Verdine, adds to growing list of licensing tie-ups with Chinese ...

GSK inks a $1.4 billion agreement to buy Aiolos Bio and its TSLP inhibitor AIO-001 for asthma, which would compete with Novartis' Tezspire.

Melbourne-based biotech VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a ...

Bengaluru: British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after ...

GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.

The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...